Eikon Therapeutics, Inc. Common Stock - EIKN - Fundamentals

Feel free to try out our engine!Whenever you're ready, pick a plan!

Best Investments/trading ideas for the weekJoin our free webinar on September23,2026.

Insider Tracker is here!

‌
‌

‌

Let's get started...

‌

Breakdown	2025 12/31	TTM
REVENUE	0	--	📊
Revenue Growth (1Y)	--	--	📊
Revenue Growth (5Y)	--	--	📊
Revenue Growth (10Y)	--	--	📊
Cost of Revenue	24	10	📊
Cost of Revenue Growth (1Y)	--	-58.05%	📊
Cost of Revenue Growth (5Y)	--	--	📊
Cost of Revenue Growth (10Y)	--	--	📊
Gross Profit	-24	-10	📊
Gross Profit Growth (1Y)	--	+58.05%	📊
Gross Profit Growth (5Y)	--	--	📊
Gross Profit Growth (10Y)	--	--	📊
Operating Expenses	315	171	📊
Operating Expenses Growth (1Y)	--	-45.81%	📊
Operating Expenses Growth (5Y)	--	--	📊
Operating Expenses Growth (10Y)	--	--	📊
Sell General Administrative	89	43	📊
Research and Development	250	211	📊
Other Income Expenses	-24	-5	📊
EBITDA	-315	-171	📊
EBITDA Growth (1Y)	--	+45.81%	📊
EBITDA Growth (5Y)	--	--	📊
EBITDA Growth (10Y)	--	--	📊
Depreciation and Amortization	24	15	📊
Operating Income	-339	-181	📊
Operating Income Growth (1Y)	--	+46.68%	📊
Operating Income Growth (5Y)	--	--	📊
Operating Income Growth (10Y)	--	--	📊
Interest Expense	1	--	📊
Pre Tax Income	-324	-251	📊
Tax Provision	0	--	📊
NET INCOME	-324	-171	📊
Net Income Growth (1Y)	--	+47.15%	📊
Net Income Growth (5Y)	--	--	📊
Net Income Growth (10Y)	--	--	📊
Basic EPS	-6.16	-4.63	📊
Diluted EPS	-6.16	-4.63	📊
Basic Average Shares	54	54	📊
Diluted Average Shares	54	54	📊

Breakdown	2025 12/31	TTM
REVENUE	0	--	📊
Revenue Growth (1Y)	--	--	📊
Revenue Growth (5Y)	--	--	📊
Revenue Growth (10Y)	--	--	📊
Cost of Revenue	24	10	📊
Cost of Revenue Growth (1Y)	--	-58.05%	📊
Cost of Revenue Growth (5Y)	--	--	📊
Cost of Revenue Growth (10Y)	--	--	📊
Gross Profit	-24	-10	📊
Gross Profit Growth (1Y)	--	+58.05%	📊
Gross Profit Growth (5Y)	--	--	📊
Gross Profit Growth (10Y)	--	--	📊
Operating Expenses	315	171	📊
Operating Expenses Growth (1Y)	--	-45.81%	📊
Operating Expenses Growth (5Y)	--	--	📊
Operating Expenses Growth (10Y)	--	--	📊
Sell General Administrative	89	43	📊
Research and Development	250	211	📊
Other Income Expenses	-24	-5	📊
EBITDA	-315	-171	📊
EBITDA Growth (1Y)	--	+45.81%	📊
EBITDA Growth (5Y)	--	--	📊
EBITDA Growth (10Y)	--	--	📊
Depreciation and Amortization	24	15	📊
Operating Income	-339	-181	📊
Operating Income Growth (1Y)	--	+46.68%	📊
Operating Income Growth (5Y)	--	--	📊
Operating Income Growth (10Y)	--	--	📊
Interest Expense	1	--	📊
Pre Tax Income	-324	-251	📊
Tax Provision	0	--	📊
NET INCOME	-324	-171	📊
Net Income Growth (1Y)	--	+47.15%	📊
Net Income Growth (5Y)	--	--	📊
Net Income Growth (10Y)	--	--	📊
Basic EPS	-6.16	-4.63	📊
Diluted EPS	-6.16	-4.63	📊
Basic Average Shares	54	54	📊
Diluted Average Shares	54	54	📊

Eikon Therapeutics, Inc. Common Stock - EIKN - Fundamentals - Financial Statements